.DAS28 was significantly higher in patients with MetS with higher number of tender joints and VAS (0-100) and most rheumatoid patients with MetS (68 %) had high disease activity. Conclusions:The increased prevalence of MetS components in RA patients, suggests greater attention be given to modifiable risk factors, including improvement of dietary habits, physical activity and blood pressure control.
INTRODUCTION:
Rheumatoid arthritis (RA) is one of the most prevalent chronic inflammatory diseases. It primarily involves the joints, but should be considered a syndrome that includes extra-articular manifestations, such as rheumatoid nodules, pulmonary involvement or vasculitis, and systemic comorbidities (1) . RA is the most common inflammatory arthritis (2) . RA is associated with increased rates of cardiovascular diseases (CVD)
(3)
. Circulating inflammatory pathways that are implicated in this risk include cytokines, acute phase reactants, immune complexes, and altered lipid particle that increase endothelial activation and potentially render atheromatous plaques unstable
(4)
. Metabolic syndrome (MetS) is multiplex risk factor for type 2 diabetes and CVDs, including insulin resistance, abdominal obesity, atherogenic dyslipidemia, high blood pressure (BP), impaired fasting blood glucose (FBG), a pro-thrombotic state, and a pro-inflammatory state
(5)
.MetS is responsible for a three-fold increase in the risk of atherosclerotic CVDs and increased mortality from CVD, as well as all-causes, compared to the general population (6) . RA and MetS are considered to be diseases with common traits that can increase the risk of CVDs . RA is associated with various components of MetS, which increase CVD mortality (9) . The frequency of MetS in RA patients ranges from 14 to 56% (10) . It was found that the risk of having a moderate-to-severe RA was higher in patients with MetS than in those without and that the disease activity correlated with the number of MetS parameters present (11) . This study was designed to determine the prevalence of MetS in patients with RA and to evaluate the relation between parameters of MetS and clinical aspects of RA.
PATIENTS AND METHODS:
This study included 150patients patients; diagnosed as having RA according to the 2010 ACR/EULAR classification criteria forRA Height and weight were measured using standard equipments and methods. The body mass index (BMI) was calculated as (kg/m 2 ). The WC was measured in the standing position using a non-stretchable tape, placed directly on skin, at end of expiration at midway between lower costal margin and upper border of iliac crest. Arterial BP measurement was done using a calibrated sphygmomanometer.
II-Joint examination and disease activity:
Examination of 28 joints of the hands, wrists, elbows, shoulders, and knees was done with count of the swollen and tender joints to calculate DAS28. The disease activity was evaluated using DAS28 (ESR) according to the equation [ DAS28 (ESR) = 0.56 × √ (TJC 28) + 0.28 √ (SJC 28) + 0.70 × ln (ESR) + 0.014 × GH (range, 0-9)]. High disease activity was considered as DAS28 > 5.1, moderate as DAS28 > 3.2-≤5.1, and low disease activity in the range 2.6-3.2. DAS28 ≤ 2.6 indicated disease remission . 
III-Laboratory investigations

RESULTS
The mean age ± SD of the patients was 45.01±11.05 years, with 126 (84%) of themwere females, and 102 (68%) were from rural areas.Only 17 (11.3%) of the patients were smokers.The mean ± SD age at the disease onset of the study population was 35.66 ± 10.60 years.The mean ± SD duration of the disease was 9.60±7.35 years. The course of the disease was progressive in all patients. Morning stiffness was recorded in 77 (51.3%) of the study population. History of hypertension was found in 28 (18.7%) of the study population and DM was documented in 19 (12.7%). History of CVDs was found in 4 (2.7%) of the study population; with history of ischemia in 3 patients and history of myocardial infarction in one patient. History of stroke was found in 1 patient (0.7%). History of use of NSAIDs was found in 146 (97.3%) of the study population. Use of steroids (prednisone/ prednisolone) was demonstrated in 61 (40.7%). Regarding DMARDs; most patients (61.3%) were using two drugs. Hydroxychloroquinewas used by 112(74.7%), methotrexate by 106 (70.7%),leflunomideby 46(30.7%), and sulfasalazine by 31(20.7%)of the study population.The main findings in general examination are shown in table 1. The mean values of DAS28 and its different components are shown in table 2. Categories of disease activity in the study population according to DAS28 are demonstrated in table 3.The CRP was positive in 136 (90.7%) of the study population, with median value of 12 mg/L (IQR: 8-25 mg/L). The RF was positive in 97 (64.7%) of the study population, with median value of 36 IU/ml (IQR: 8-128 IU/ml). The anti-CCP was positive in 99 (66%) of the study population.The mean ± SD level of FBG was 86.53 ± 28.75 mg/dl.The mean ± SD level of TG was 124.64 ± 39.55 mg/dl, TC was 193.02 ± 42.42 mg/dl, and HDL-C was 46.7 ± 8.81mg/dl. The study population was divided according to the presence of MetS (JIS definition with Egyptian cut-off values of WC) into two groups: RA patients with MetS (n= 69) and RA patients without MetS (n= 81). The demographic data of the study groups are shown in table 5.The arthritis history and therapeutic history of the study groups are shown in table 6. 
DISCUSSION
In the current study; most patients were females (84 %) with mean age 45.01 ± 11.05 years and disease duration 9.60±7.35 years. More than half of patients (52 %) had severe disease activity according to DAS28. This may be explained by the setting from which they were recruited (a tertiary-level referral hospital) and no use of biological theray in any of the patients. In this study the prevalence of MetS in RA patients was 48% (ATPIII definition), 52 % (IDF definition), and 46 % (JIS definition with Egyptian cutoff), respectively. This was higher than that reported in a previous study on 3209 randomly selected Egyptian population; 42.5% (ATPIII definition), 44.3% (IDF definition), and 41.5% (JIS definition with Egyptian cut-off), respectively
(17)
. This indicates that presence of RA may increase possibility of presence of MetS. This prevalence was near that previously reported in RA patients; 51.4 % (ATPIII) and 53.4 % (IDF definition) in 107 Brazilian rheumatoid patients , and a recent Brazilian report of 50.3 % (ATPIII)
. However; this was lower than previous Italian study that reported 55.5% . The reported prevalence in the current study is one of the highest prevalences all over the world. On the contrary; this prevalence was higher than that previously reported in RA patients; 40.1% (ATPIII) and 45.4 % (IDF) in 387 British rheumatoid patients . The difference in prevalence may be related to ethnicity, geographic area, nutritional habits, and different inclusion criteria and disease characteristics. In this study the most prevalent component of MetS was central obesity (75.3-92 % according to the used definition) and was more common in females; while the lowest prevalence was high . This may be related to the socioeconomic, lifestyle, and nutritional changes which have been occurring in the Egyptian community; towards the unhealthy pattern. In the current study; patients with Mets were significantly older than those without MetS. This was in accordance with previous reports (8, 19, (30) (31) (32) . This may be related to the fact that age is a variable known to increase the frequency of comorbidities, MetS among them. In this study; the age of disease onset was significantly higher in patients with MetS with no significant difference of disease duration. This was in accordance with previous reports (8, 10, 19, 27) . This enforces the value of age of patients over the disease duration in development of MetS.On the other side; other studies reported longer duration of RA in rheumatoid patients with MetS (11, 23, 30) . This may be related to different age groups, duration of the disease, and the used drugs in these studies. In the present study; there was no statistically significant difference between RA patients with and without MetS as regards used NSAIDs, steroids and DMARDs. This was in accordance with previous reports (8, 19, 32) . On the contrary; a previous study showed a significant association between the absence of MetS and the use of MTX and suggested the possibility of a drugspecific protection mechanism for MTX . This may be explained by that; in the current study; the use of NSAIDs and glucocorticoids may have compensated for the protective effect of MTX and hydroxychloroquine. In the current study; DAS28 was significantly higher in patients with MetS with higher number of tender joints and VAS (0-100). This was in accordance with previous reports . On the opposite side; a previous study failed to confirm this finding (33) . The authors explained their findings that the aggressive treatment with DMARDs and life style modifications may alter MetS prevalence. In the present study; most RA patients with MetS (68 %) had high disease activity. This was in accordance with previous studies (19, 34, 35) . This suggests that inflammation could play a role in the development of metabolic disturbance in RA patients. In the present study; there was no statistically significant difference between rheumatoid patients with and without MetS as regards immunological investigations (CRP, RF, and anti-CCP). This was in accordance with previous reports . On the contrary; higher ESR and CRP were found in RA patients with MetS . This can be explained that the RA patients in the last study were treatment naïve. In the current study; hypertension and use of antihypertensive drugs was reported in 28 (18.7%) of the patients. However; elevated BP was found in higher proportion (54%). This was in accordance with previous reports of high prevalence of raised BP in RA (11, 36, 37) . Moreover; Panoulas et al. (2007) reported that hypertension is underdiagnosed, especially in young RA patients. This indicates the value of follow up of BP in rheumatoid patients to detect hypertension early and avoid development of CVDs. None of the rheumatoid patients in this study was treated for dyslipidemia. However; raised TG was found in 38 (25.3 %) of patients and decreased HDL-C was detected in 85 (56.7 %) of the patients. The increased levels of dyslipidemia in RA patients were previously reported (11, 38, 39) . A recent study reported high prevalence of undiagnosed hypercholesterolemia in patients with RA
(40)
. These findings demonstrate the importance of searching for dyslipidemias in rheumatoid patients in order to decrease CVD events and all-cause mortality. In the present study; only 19 (12.7%) of the patients had DM; while raised FBG was found in 36 (24%) of the patients. This was in accordance with previous reports (8, 31) . A recent study demonstrated that impaired FBG was a strong predictor of T2D after one year of follow up in rheumatoid patients (41) . This finding indicates the importance of studying impaired FBG in rheumatoid patients to avoid further development of T2D. Despite interesting findings of this study, it was limited by its crosssectional design not allowing conducting any cause-effect inferences on relationship between RA characteristics and MetS. A longitudinal study should be designed to establish the casualty of these findings. Another limitation is the risk of selection bias since our center is a tertiary referral center with recruitment of mostly active and severe disease patients, and potentially leading to an overestimation of the prevalence of MetS. Multicenter studies with larger number of rheumatoid patients are warranted in order to determine prevalence of MetS in Egyptian patients with RA.
